Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Revenue (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Revenue for 7 consecutive years, with $33000.0 as the latest value for Q1 2026.

  • For Q1 2026, Revenue fell 89.56% year-over-year to $33000.0; the TTM value through Mar 2026 reached $34000.0, down 99.78%, while the annual FY2024 figure was $15.0 million, 1766.46% up from the prior year.
  • Revenue hit $33000.0 in Q1 2026 for Barinthus Biotherapeutics, up from $1000.0 in the prior quarter.
  • Across five years, Revenue topped out at $17.1 million in Q2 2022 and bottomed at $1000.0 in Q2 2025.
  • Average Revenue over 5 years is $6.1 million, with a median of $3.3 million recorded in 2022.
  • Year-over-year, Revenue surged 645800.0% in 2022 and then plummeted 98.04% in 2023.
  • Barinthus Biotherapeutics' Revenue stood at $6.5 million in 2022, then plummeted by 94.83% to $334000.0 in 2023, then surged by 4381.74% to $15.0 million in 2024, then plummeted by 99.99% to $1000.0 in 2025, then surged by 3200.0% to $33000.0 in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $33000.0, $1000.0, and $316000.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.